Skip to main content
Tessa NewsLink
Paste a health news link, or browse
Latest checks

Source study found

Story checked

Previously unrecognized immune cells may drive harmful blood vessel growth in blinding eye diseases (opens in a new tab)

medicalxpress.com · 2026-10-26

Short answerEvidenceSource

Short answer

Mostly not supported

Mostly not supported.

One claim goes further than the study. 3 other points were not covered by the paper.

  • 1 supported
  • 1 overstated
  • 3 not covered

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

Mostly not supported

One claim overstates the study. One of five checks out. Three claims the study doesn't address.

  • 1 supported
  • 1 overstated
  • 3 not covered
Open claim evidence
3
Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

5 claims in this story

Showing all 5 claimsChoose a verdict to focus the list.

Claim 1 of 5OverstatedA Northwestern Medicine study identified a previously unrecognized population of immune cells that appears to fuel harmful blood vessel growth in multiple blinding eye diseases.View evidenceHide evidence

Why this verdict

The paper profile supports identification of a conserved MoPOM macrophage subtype enriched in ocular neovascular disease samples and causal necessity in a mouse laser-CNV model. However, the headline-level framing that the cells appear to fuel harmful vessel growth across multiple blinding human eye diseases goes beyond the abstract-level evidence: human/multiple-disease evidence is mainly enrichment/localization, while functional causality is shown in mice.

1

Study evidence

A conserved macrophage subtype characterized by high SPP1, FABP5, and IL7R expression (MoPOM) was identified via integrated single-cell RNA-seq analysis and was over-represented in ocular neovascular disease samples across human and mouse datasets.

“we integrated 13 single-cell RNA sequencing datasets from human and mouse eyes comprising 173 unique samples”
2

Study evidence

Fate mapping and subtype-specific depletion in mice show MoPOM are monocyte-derived and necessary for laser-induced choroidal neovascularization; depletion reduced CNV in the model.

“we... specifically depleted them, showing that they are ... necessary for laser-induced choroidal neovascularization in mice”
Claim 2 of 5Not coveredIn mouse models, selectively depleting IL7R-positive macrophages reduced abnormal blood vessel growth by more than 40%, suggesting the cells are required for disease development.View evidenceHide evidence

As statedmore than 40%

Why this verdict

The profile supports the qualitative finding that targeted depletion of MoPOM in mice reduced or prevented laser-induced CNV and was interpreted as showing necessity in that model. But the abstract-level profile does not report the claimed magnitude of more than 40%, nor does it specify enough about selectively depleting IL7R-positive macrophages to verify the exact formulation.

1

Study evidence

Fate mapping and subtype-specific depletion in mice show MoPOM are monocyte-derived and necessary for laser-induced choroidal neovascularization; depletion reduced CNV in the model.

“we... specifically depleted them, showing that they are ... necessary for laser-induced choroidal neovascularization in mice”
Claim 3 of 5Not coveredHigh-resolution spatial transcriptomics on donated human eye tissue found the macrophages were located almost exclusively near choroidal neovascular membranes, the destructive lesions responsible for vision loss in wet AMD.View evidenceHide evidence

As statedalmost exclusively

Why this verdict

The profile supports that high-resolution spatial RNA-seq on human donor tissue localized MoPOM to human choroidal neovascular membranes. The stronger wording that the macrophages were located 'almost exclusively near' those membranes is a quantitative/exclusivity claim not provided in the abstract-level evidence.

1

Study evidence

High-resolution spatial RNA sequencing of six human donors localized the monocyte-derived pro-angiogenic ocular macrophage subtype (MoPOM; SPP1+, FABP5+, IL7R+) to human choroidal neovascular membranes.

“we performed a high-resolution spatial RNA sequencing experiment on six human donors”
Claim 4 of 5Not coveredTreating mice with an MMP14 inhibitor reduced lesion size by more than 50%, and the researchers said suppressing signals from these cells may offer a new treatment option for patients facing blindness.View evidenceHide evidence

As statedmore than 50%

Why this verdict

The profile supports MMP14 expression in human neovascular membranes and decreased CNV after MMP14 inhibition in mice, consistent with MMP14 as a potential target. The abstract-level profile does not verify the claimed more-than-50% lesion-size reduction, inhibitor details, or the strength of translation to a new patient treatment option beyond a potential/future therapeutic direction.

1

Study evidence

MMP14 is expressed in human choroidal neovascular membranes, present in the identified pro-angiogenic macrophage subtype and in other lesion cells; this expression was used to nominate MMP14 as a potential therapeutic target.

“These macrophages and other cells in neovascular membranes expressed MMP14, a potential therapeutic target”
2

Study evidence

MMP14 inhibition decreased choroidal neovascularization in mice.

“MMP14 inhibition decreased choroidal neovascularization in mice”
Claim 5 of 5SupportedThe study found a distinct subtype of macrophage, dubbed monocyte-derived pro-angiogenic ocular macrophages (MoPOMs), that was consistently enriched in subjects with eye diseases featuring harmful blood vessel growth, including wet AMD and proliferative diabetic retinopathy.View evidenceHide evidence

Why this verdict

The abstract-level profile states that integrated human and mouse scRNA-seq data identified a distinct SPP1/FABP5/IL7R-high macrophage subtype, termed MoPOM, that was over-represented in ocular neovascular disease samples across species. The story’s associational enrichment framing is broadly aligned with this evidence.

1

Study evidence

A conserved macrophage subtype characterized by high SPP1, FABP5, and IL7R expression (MoPOM) was identified via integrated single-cell RNA-seq analysis and was over-represented in ocular neovascular disease samples across human and mouse datasets.

“we integrated 13 single-cell RNA sequencing datasets from human and mouse eyes comprising 173 unique samples”
Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

  • The human spatial transcriptomics evidence came from six donors and is ex vivo localization evidence, not proof of functional causation in human disease.

    The story mentions donated human tissue and future translation but does not appear to acknowledge the small donor number or that spatial co-localization alone is associational.

    From spatial_transcriptomics_on_ex_vivo_human_CNV_tissue

  • MoPOM discovery was based on pooled re-analysis of existing scRNA-seq datasets and computational clustering/annotation, which may be affected by dataset composition and technical differences.

    The story conveys the discovery but does not mention the computational meta-analysis nature of the evidence or its dataset-composition limitations.

    From scRNA-seq integration/meta-analysis

8 things the story did carry across
  • Integrated analysis of 13 human and mouse single-cell RNA-seq datasets identified a conserved SPP1/FABP5/IL7R-high macrophage subtype termed MoPOM.
  • MoPOM was over-represented or enriched in ocular neovascular disease samples across human and mouse datasets.
  • Mouse fate mapping showed MoPOM are monocyte-derived.
  • Targeted depletion of MoPOM in a mouse laser-induced CNV model showed the cells are necessary for CNV development in that model.
  • High-resolution spatial RNA-seq of ex vivo human donor tissue localized MoPOM to human choroidal neovascular membranes.
  • MMP14 was expressed in MoPOM and other cells in neovascular membranes, leading to nomination of MMP14 as a potential therapeutic target.
  • MMP14 inhibition decreased choroidal neovascularization in mice.
  • The causal depletion and MMP14-inhibition evidence comes from mouse laser-induced CNV models, with uncertain generalizability to human wet AMD, proliferative diabetic retinopathy, or patient treatment outcomes.
Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

6

Evidence read

study summary

Lead result

in vivo animal

1Lead resultin vivo animalDemonstrate in mice that MoPOM are monocyte-derived and are necessary for choroidal neovascularization (CNV), using fate mapping and targeted depletion in a laser-induced CNV model.in vivo mouse depletion experimentExpand

In plain English

In a mouse laser-induced choroidal neovascularization (CNV) model, fate-mapping and targeted depletion experiments reported in the paper show that the identified Monocyte-derived Pro-angiogenic Ocular Macrophage (MoPOM) population is monocyte-derived and is necessary for development of CNV: specific depletion of these cells reduced or prevented laser-induced CNV in mice.

Key findings

  • Fate mapping and subtype-specific depletion in mice show MoPOM are monocyte-derived and necessary for laser-induced choroidal neovascularization; depletion reduced CNV in the model.
“we... specifically depleted them, showing that they are ... necessary for laser-induced choroidal neovascularization in mice”
What this piece can’t prove

3 further details could not be confirmed from the summary.

2in silicoIdentify a conserved pro-angiogenic ocular macrophage subtype (MoPOM; high SPP1/FABP5/IL7R) that is enriched in ocular neovascular disease across human and mouse, using integrated single-cell transcriptomic data.scRNA-seq integration/meta-analysisExpand

In plain English

Integrated analysis of 13 human and mouse single-cell RNA-seq datasets (173 samples; 99,184 mononuclear phagocytes) identified a conserved macrophage subtype characterized by high SPP1, FABP5, and IL7R expression (termed MoPOM) that was over-represented in ocular neovascular disease samples across species.

Key findings

  • A conserved macrophage subtype characterized by high SPP1, FABP5, and IL7R expression (MoPOM) was identified via integrated single-cell RNA-seq analysis and was over-represented in ocular neovascular disease samples across human and mouse datasets.
“we integrated 13 single-cell RNA sequencing datasets from human and mouse eyes comprising 173 unique samples”
What this piece can’t prove
  • Finding is derived from pooled re-analysis of existing scRNA-seq datasets; results may be influenced by dataset composition, sampling, and technical differences between studies.
  • Subtype definition is based on transcriptional marker expression and computational clustering; functional attribution (pro-angiogenic activity) requires orthogonal experimental validation.
3in vivo animalDemonstrate in mice that MoPOM are monocyte-derived and are necessary for choroidal neovascularization (CNV), using fate mapping and targeted depletion in a laser-induced CNV model.in vivo fate mapping and depletionExpand

In plain English

In mice, fate mapping and targeted depletion experiments show that the identified pro-angiogenic ocular macrophage subtype (MoPOM) is monocyte-derived and is necessary for laser-induced choroidal neovascularization.

Key findings

  • Mouse fate mapping and targeted depletion experiments indicate the MoPOM subtype is monocyte-derived and required for development of laser-induced choroidal neovascularization.
“We fate mapped these cells... showing that they are monocyte-derived”
What this piece can’t prove

3 further details could not be confirmed from the summary.

4ex vivo humanLocalize MoPOM in human choroidal neovascular membranes using high-resolution spatial transcriptomics.spatial transcriptomics on ex vivo human CNV tissueExpand

In plain English

High-resolution spatial RNA sequencing of ex vivo human ocular tissue from six donors identified localization of a monocyte-derived pro-angiogenic macrophage subtype (MoPOM; SPP1+, FABP5+, IL7R+) to human choroidal neovascular (CNV) membranes.

Key findings

  • High-resolution spatial RNA sequencing of six human donors localized the monocyte-derived pro-angiogenic ocular macrophage subtype (MoPOM; SPP1+, FABP5+, IL7R+) to human choroidal neovascular membranes.
“we performed a high-resolution spatial RNA sequencing experiment on six human donors”
What this piece can’t prove
  • Small number of human donors reported in abstract (n = 6), limiting generalizability.
  • Abstract lacks detailed information on tissue procurement, spatial transcriptomics platform, resolution, and computational deconvolution or signature-scoring methods.
  • Spatial co-localization of a transcriptional signature does not by itself demonstrate functional contribution to neovascularization in human tissue (association, not causation).

1 further detail could not be confirmed from the summary.

5ex vivo humanIdentify MMP14 as a potential therapeutic target in neovascular membranes and test whether MMP14 inhibition reduces CNV in mice.High-resolution spatial RNA sequencing, ex vivo human choroidal/neovascular membranesExpand

In plain English

High-resolution spatial RNA sequencing of human neovascular membranes identified MMP14 expression in the pro-angiogenic macrophage subtype and other lesion cells, leading to nomination of MMP14 as a potential therapeutic target for choroidal neovascularization.

Key findings

  • MMP14 is expressed in human choroidal neovascular membranes, present in the identified pro-angiogenic macrophage subtype and in other lesion cells; this expression was used to nominate MMP14 as a potential therapeutic target.
“These macrophages and other cells in neovascular membranes expressed MMP14, a potential therapeutic target”
What this piece can’t prove
  • Small sample size (six human donors) reported for the spatial RNA-seq experiment.
  • Nomination of MMP14 is based on expression patterns; functional relevance requires independent validation.
  • Spatial transcriptomic approaches may have limited resolution for unambiguous cell-type assignment and quantitative comparison across lesions.
6in vivo animalIdentify MMP14 as a potential therapeutic target in neovascular membranes and test whether MMP14 inhibition reduces CNV in mice.In vivo mouse CNV pharmacologic/biologic inhibition experimentExpand

In plain English

The authors report that MMP14 is expressed in human neovascular membranes and that inhibition of MMP14 reduced choroidal neovascularization (CNV) in a mouse CNV model, supporting MMP14 as a potential therapeutic target for ocular neovascular disease.

Key findings

  • MMP14 inhibition decreased choroidal neovascularization in mice.
“MMP14 inhibition decreased choroidal neovascularization in mice”
What this piece can’t prove

3 further details could not be confirmed from the summary.

Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Papers considered

The selected paper, plus nearby candidates.

PubMed, Europe PMC, Crossref · 15 candidate papers

Candidate

Fig. 8. Choroidal neovascularization: a, ophthalmoscopic picture corresponding to chorioretinitis in remission and inactive choroidal neovascularization; b, optical coherence tomography angiography showing active choroidal neovascularization in the chorioretinal focus.

Crossref

Source (opens in a new tab)

And 9 more candidates considered.